bacterial meningitis

in review 6 min read Updated 2026-10-18
bacterial meningitis

Medical emergency — antibiotics within 60 minutes. Empiric: ceftriaxone + vancomycin, + ampicillin if Listeria risk (>50, pregnancy, immunocompromise). Dexamethasone before or with the first antibiotic dose — mortality benefit in pneumococcal meningitis (European Dexamethasone Study (2002)). Add acyclovir if any encephalitic features. Blood cultures → antibiotics → then CT/LP; CT first only with specific indications.

bacterial meningitis empiric antibiotics
  • blood cultures × 2 immediately; LP before antibiotics only if it causes no delay
  • dexamethasone 10 mg IV q6h × 4 days — BEFORE or WITH first antibiotic dose
  • ceftriaxone 2 g IV q12h — give first
  • if age >50, pregnancy, or immunocompromised: ampicillin 2 g IV q4h — give second
  • vancomycin 25–30 mg/kg IV load (~2 g), then per local protocol (continuous infusion or AUC-guided) — give last
  • if encephalitis features (behaviour change, focal signs, seizures): acyclovir 10 mg/kg IV q8h
  • ceftriaxone allergy: meropenem 2 g IV q8h + vancomycin — see penicillin allergy
  • droplet precautions until 24 h of effective therapy
  • tailor to CSF culture/PCR at 48–72 h; stop dexamethasone if not pneumococcal
local antibiogram

Ceftriaxone-non-susceptible S. pneumoniae is uncommon but present in Canada — empiric vancomycin continues until susceptibilities return. Penicillin-resistant isolates are often ceftriaxone-susceptible → check the ceftriaxone MIC before continuing vancomycin.


when to suspect

Classic triad (fever + neck stiffness + altered mental status) is present in <50%, but absence of all three makes meningitis very unlikely (~99–100% sensitivity for ≥1 — Attia, JAMA. 1999).

featuremeningitisencephalitis
dominant early featurefever, headache, neck stiffnessaltered mental status, behaviour change
focal deficits / seizureslateearly
next stepas below+ acyclovir, MRI, HSV/VZV PCR
  • acute fever + headache + any of: neck stiffness, photophobia, altered consciousness, petechial/purpuric rash
  • Kernig and Brudzinski signs: low sensitivity — absence does not exclude meningitis
  • jolt accentuation: originally reported ~97% sensitive; later studies much lower — a negative test does not exclude meningitis
  • meningococcaemia can present as purpura + shock without meningism
  • fever + confusion/behaviour change with modest lymphocytic CSF → acyclovir now, HSV PCR, MRI temporal lobes; early HSV PCR can be falsely negative → repeat at 3–7 days if suspicion persists → encephalitis
  • basal meningitis (cranial nerve palsies, long-tract signs, subacute course) → think TB, Listeria, Cryptococcus, syphilis, Lyme

CT before LP — indications

LP can proceed without CT in most patients. CT first only if (IDSA):

  • focal neurological deficit
  • new-onset seizure (within 1 week)
  • papilloedema
  • abnormal level of consciousness
  • immunocompromised (HIV, transplant, immunosuppressive therapy)
  • history of CNS disease (mass, stroke, focal infection)

A normal CT does not exclude raised ICP.

do not delay antibiotics for imaging

If CT is needed before LP → blood cultures → dexamethasone + empiric antibiotics → CT → LP. Pre-treatment lowers CSF culture yield within hours (meningococcus can sterilise within ~2 h), but cell count, protein, glucose, and PCR remain interpretable.


CSF interpretation

parameterbacterialviralTB
opening pressure↑↑ (>30 cm H₂O)normal–↑↑↑
WBC>1000 × 10⁶/L (neutrophilic)10–500 (lymphocytic)100–500 (lymphocytic)
protein↑↑ (>1.0 g/L)normal–↑↑↑
glucose↓↓ (CSF:serum <0.4)normal↓↓
Gram stainpositive in 60–90%negativeAFB rarely positive

Send: cell count + differential, protein, glucose (paired serum), Gram stain, culture, HSV/enterovirus PCR, and multiplex PCR if available. Immunocompromised → add cryptococcal antigen.

Partially treated meningitis: lymphocytic CSF, lower protein, sterile cultures — mimics viral → send PCR and treat empirically.


empiric therapy — detail

by risk group

patient grouplikely organismsempiric regimen
18–50, immunocompetentS. pneumoniae, N. meningitidisceftriaxone 2 g IV q12h + vancomycin
>50, pregnant, or immunocompromisedabove + Listeria monocytogenesceftriaxone + vancomycin + ampicillin 2 g IV q4h (Listeria is intrinsically cephalosporin-resistant)
post-neurosurgical / shunt / drainS. aureus, CoNS, C. acnes, Gram-negatives incl. Pseudomonasmeropenem 2 g IV q8h + vancomycin; no dexamethasone; ID consult
basilar skull fractureS. pneumoniae, H. influenzae, GASceftriaxone + vancomycin

Give the β-lactam before vancomycin — earlier effective Gram-negative/pneumococcal cover (Amoah, Clin Infect Dis. 2021: β-lactam-first associated with lower mortality in bacteraemia).

Post-neurosurgical (healthcare-associated ventriculitis/meningitis, IDSA 2017):

  • remove infected shunt/hardware → external ventricular drain; ± rifampicin for staphylococci on retained hardware
  • avoid piperacillin-tazobactam (poor CNS penetration); ceftazidime/cefepime as definitive therapy once susceptibility confirmed
  • reimplant a new shunt only after CSF cultures have been negative for 7–10 days (organism-dependent)

penicillin allergy

allergy historyapproach
immediate reaction to penicillin (incl. anaphylaxis)ceftriaxone — no shared side chain
ceftriaxone allergymeropenem 2 g IV q8h + vancomycin
SCAR, serum sickness, AIN, cytopaenia to any β-lactamavoid all β-lactams → vancomycin + moxifloxacin (IDSA) ± TMP-SMX for Listeria; ID consult
Listeria cover needed + β-lactams avoidedTMP-SMX 5 mg/kg (TMP) IV q6h

dexamethasone

European Dexamethasone Study (2002): dexamethasone 10 mg IV q6h × 4 days reduced mortality and unfavourable outcome in pneumococcal meningitis; also reduces hearing loss.

  • give before or with first antibiotic dose; ESCMID allows starting up to 4 h after the first antibiotic dose — not beyond
  • continue × 4 days if S. pneumoniae; stop if another pathogen confirmed or meningitis excluded
  • not for post-neurosurgical meningitis
  • Listeria: stop — associated with higher mortality in neurolisteriosis (MONALISA, Lancet Infect Dis. 2017)
  • may lower vancomycin CSF penetration — some add rifampicin for ceftriaxone-resistant pneumococcus

targeted therapy once pathogen known

organismpreferredduration
S. pneumoniae — penicillin MIC ≤0.06penicillin G 4 MU IV q4h (or ceftriaxone)10–14 days
S. pneumoniae — penicillin-resistant, ceftriaxone-susceptibleceftriaxone 2 g IV q12h alone10–14 days
S. pneumoniae — ceftriaxone-resistant (MIC >1)ceftriaxone + vancomycin (± rifampicin)10–14 days
N. meningitidispenicillin G or ceftriaxone7 days
L. monocytogenesampicillin 2 g IV q4h ± gentamicin21 days
H. influenzaeceftriaxone 2 g IV q12h7 days
GBSpenicillin G or ampicillin14–21 days

post-exposure prophylaxis

meningococcal contacts

  • close contacts: household, room/bed-sharing, kissing/shared utensils, childcare contacts, HCWs with unprotected exposure to respiratory secretions (intubation, suctioning, mouth-to-mouth), airline passengers seated adjacent on flights ≥8 h
  • chemoprophylaxis ideally within 24 h, up to 10 days after last exposure: ciprofloxacin 500 mg PO single dose, or rifampicin 600 mg PO q12h × 2 days, or ceftriaxone 250 mg IM single dose (preferred in pregnancy)
  • immunoprophylaxis for close contacts when the serogroup is vaccine-preventable: Men-C-ACYW (A, C, Y, W) or 4CMenB (B), per NACI/public health
  • notify public health immediately

Prepared 2026-10-18. Not yet verified — check every number against the sources.

Key references

+6 more sources

Suggest a correction bacterial meningitis